Joanne F. Chou

May 22, 2024 | onlinelibrary.wiley.com | Emily S. Tonorezos |Joanne F. Chou |Chaya Moskowitz |Wendy M. Leisenring

CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. REFERENCES 1, , , et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Biomarkers Prev. 2015; 24(4): 653-663. doi:10.1158/1055-9965.Epi-14-1418 2, . Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer. 2014; 14(1): 61-70. doi:10.1038/nrc3634 3, , , et al.

Mar 4, 2024 | erc.bioscientifica.com | Darren Cowzer |Ronak Shah |Joanne F. Chou |Ritika Kundra

Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal. The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media. More information is on the Reasons to publish page.

Nov 9, 2023 | ascopubs.org | Mary Yeboah Afihene |Joanne F. Chou |Olusegun Isaac Alatise |Jerry Ndumbalo

Similarities and differences in the care for patients with HCC in Africa are reported. This reconfirms the major gaps in access and availability especially in C and marginally less so in EW. This is a call for concerted multidisciplinary efforts to achieve and sustain a reduction in incidence and mortality from HCC in Africa. Of 461 participants from all relevant subspecialties, 372 were from Africa. Most African participants provided hepatitis B vaccination and treatment for hepatitis B and C.

Sep 1, 2023 | thelancet.com | Samuel Cytryn |Ryan H. Moy |Darren Cowzer |Joanne F. Chou

Research in contextEvidence before this studyWe searched PubMed for published studies from database inception until April 1, 2023, using the search terms (“gastric cancer” OR “gastroesophageal cancer” OR “esophageal cancer”) AND (“regorafenib” OR “PD-1 inhibitor” OR “PD-L1 inhibitor”). The search was restricted to clinical trials with no language restrictions.

May 31, 2023 | ascopubs.org | Catherine O'Connor |Joanne F. Chou |Carly Schwartz |Anna Varghese

Background: Maintenance olaparib improves PFS in gBRCA1/2m (core HRD) in mPDAC (Golan, NEJM 2019). Whether other HRD indicators, such as gene mutations other than gBRCA1/2m (non-Core HRD, Cohort B) and exceptional platinum responders (Cohort C, response > 6 months) may benefit from PARPi in mPDAC remains unanswered. We hypothesized that pembrolizumab and olaparib (POLAR) combination may improve outcome by immunogenic cell death.